Physician profile
Sunny Schlabach
NPI 1629778527
$1,331.17
in general payments reported to CMS, 2019-2025
15 companies · $578 in 2025
The $578 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $344 · 2024: $409 · 2025: $578.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,284 · Education: $46.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,284.26 |
| Education | $46.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $260.43 | 2023-2025 | Caplyta |
| Abbvie INC. | $229.76 | 2023-2024 | |
| Alkermes, INC. | $218.67 | 2024-2025 | Aristada, Lybalvi |
| Vanda Pharmaceuticals INC. | $139.05 | 2025 | Fanapt, Hetlioz |
| Teva Pharmaceuticals USA, INC. | $111.46 | 2023-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Neurocrine Biosciences, INC. | $57.31 | 2023-2024 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $57.06 | 2024 | Cobenfy |
| Otsuka America Pharmaceutical, INC. | $54.81 | 2023-2025 | Rexulti, Abilify Asimtufii |
| Axsome Therapeutics, INC. | $45.94 | 2024-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $41.00 | 2024-2025 | Invega Trinza, Invega Sustenna |
| Supernus Pharmaceuticals, INC. | $30.68 | 2025 | Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $28.07 | 2023-2024 | Trintellix |
| Tris Pharma INC | $21.25 | 2024 | Dyanavel Xr |
| Noven Therapeutics, LLC | $20.81 | 2024 | Xelstrym |
| Idorsia Pharmaceuticals US INC | $14.87 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sunny Schlabach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.